Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO)’s stock price dropped 16.7% during trading on Monday . The stock traded as low as C$0.31 and last traded at C$0.35. Approximately 86,380 shares changed hands during mid-day trading, an increase of 542% from the average daily volume of 13,464 shares. The stock had previously closed at C$0.42.
Aptose Biosciences Price Performance
The company has a current ratio of 0.80, a quick ratio of 5.41 and a debt-to-equity ratio of 670.80. The business’s 50 day moving average price is C$0.41 and its two-hundred day moving average price is C$0.65. The stock has a market cap of C$5.98 million, a P/E ratio of -0.06 and a beta of 1.36.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- What is an Earnings Surprise?
- Time to Board Carnival Cruise Lines’ Stock Price Rally
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Is Warner Bros. Discovery Stock a Buy After Recent Drop?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
